ObjectiveTo explore the clinical effects of tirofiban combined with butylphthalide injection in the treatment of progressive cerebral infarction. MethodsA total of 120 patients with progressive cerebral infarction admitted to our hospital from April 2018 to March 2019 were selected as the research objects, and they were divided into control group and observation group by the random number method, with 60 cases in each group. The control group was treated with routine treatment, based on which the observation group was additionally treated with tirofiban and butylphthalide injection, for a two-week continuous treatment. The National Institute of Health Stroke Scale (NIHSS) scores, Barthel index scores, platelet aggregation rate, low-shear whole blood viscosity, high-shear whole blood viscosity before and after treatment were compared between the two groups. The clinical efficacy and adverse reactions of the two groups were also compared. ResultsBefore treatment, there were no statistically significant differences in NIHSS and Barthel index scores, platelet aggregation rate, low-shear whole blood viscosity, and high-shear whole blood viscosity between the two groups (P＞0.05). After 2 weeks of treatment, the NIHSS scores of the two groups significantly decreased, while the Barthel index scores significantly increased; compared with the control group, the observation group yielded a lower NIHSS score, while a higher Barthel index score, with statistically significant differences (P＜0.05). The platelet aggregation rate, low-shear whole blood viscosity, and high-shear whole blood viscosity significantly decreased in both groups, and the observation group yielded lower levels of the above-mentioned indicators as compared with the control group, with statistically significant differences (P＜0.05). The total effective rate of treatment in the observation group was significantly higher than that in the control group, with a statistically significant difference (P＜0.05). During the treatment, there was no statistically significant difference in the incidence of total adverse reactions between the two groups (P＞0.05). ConclusionOn the basis of conventional treatment, the combined treatment of tirofiban and butylphthalide can significantly improve the neurological function of patients with progressive cerebral infarction, improve the activities of daily living, reduce platelet aggregation, reduce blood viscosity, and it also can significantly improve the clinical therapeutic effect without increasing the adverse reactions in patients.

无